Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $3.7M fell 24.2% year over year, behind the +13.2% change in trailing-twelve-month research & development. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Research & development amounted to 12.6% of revenue in FY2025, up 5.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -24.2% toward the trailing-twelve-month pace of +13.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 23.33M USD
- Year-over-year change
- +21.4%
- 4-year CAGR
- +11.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.33M | +21.4% |
| FY2024 | 2024-12-31 | 19.22M | +11.2% |
| FY2023 | 2023-12-31 | 17.28M | -5.9% |
| FY2022 | 2022-12-31 | 18.37M | +20.7% |
| FY2021 | 2021-12-31 | 15.22M | — |
Research & Development vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 research & development of $21.15M is the 7th highest of the 9 companies compared; the peer median is $46.58M.
- Its year-over-year change of +13.2% is the 3rd highest of 9, against a peer median of -4.5%.
- Research & development amounts to 10.1% of revenue for MRVI, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Mar 2026 | $87.86M | -27.1% | -20.4% | 54.9% | |
| LTM Jun 2026 | $55.23M | +14.4% | +7.2% | 7.0% | |
| LTM Sep 2026 | $37.92M | +31.1% | +3.7% | 6.1% | |
| LTM Mar 2026 | $22.48M | -43.6% | -11.4% | 26.1% | |
| LTM Jun 2026 | $21.15M | +13.2% | +8.3% | 10.1% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Mar 2026 | $8.14M | +5.5% | -20.0% | 8.2% | |
| Peer median (excluding MRVI) | $46.58M | -4.5% | -5.5% | 8.0% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 799.24M | 883M | 288.95M | 259.19M | 185.74M |
| Cost of Revenue | 140.56M | 168.96M | 148.74M | 150.88M | 152.35M |
| Gross Profit | 658.68M | 714.04M | 140.2M | 108.31M | 33.39M |
| Gross Margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.0% |
| Research & Development | 15.22M | 18.37M | 17.28M | 19.22M | 23.33M |
| Selling, General & Admin | 100.06M | 129.26M | 151.39M | 161.77M | 171.47M |
| Operating Expenses | 104.03M | 139.83M | 171.85M | 343.93M | 40.13M |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| EBITDA | 585.78M | 609.99M | 712.41M | (156.92M) | (147.51M) |
| EBITDA Margin | 73.3% | 69.1% | 246.6% | -60.5% | -79.4% |
| Operating Income | 554.65M | 574.22M | (31.65M) | (235.62M) | (6.74M) |
| Operating Margin | 69.4% | 65.0% | -11.0% | -90.9% | -3.6% |
| Interest Income | 0 | 2.34M | 27.73M | 27.4M | 23.95M |
| Interest Expense | 30.26M | 20.41M | 45.89M | 47.7M | 26.99M |
| Other Income / Expenses | (23.88M) | (22.74M) | 649.38M | (25.87M) | (228.24M) |
| Income Before Tax | 530.77M | 551.47M | 617.74M | (261.48M) | (234.97M) |
| Pre-Tax Margin | 66.4% | 62.5% | 213.8% | -100.9% | -126.5% |
| Income Tax Expense | 61.52M | 60.81M | 756.11M | (1.86M) | (4.21M) |
| Net Income | 182.04M | 220.21M | (119.03M) | (144.85M) | (130.77M) |
| Net Margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (Basic) | 1.59 | 1.67 | (0.90) | (1.05) | (0.91) |
| EPS (Diluted) | 1.56 | 1.67 | (0.90) | (1.05) | (0.91) |
| Weighted Avg Shares | 114.79M | 131.54M | 131.92M | 137.91M | 145.07M |
| Weighted Avg Shares (Diluted) | 121.97M | 131.7M | 131.92M | 137.91M | 145.07M |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.